This site is intended for healthcare professionals

Listen or subscribe on

This podcast series was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this podcast was provided by OmniaMed Communications. GPnotebook has had no input into the content of this podcast series. © 2022 Sanofi

Socioeconomic barriers and disparities to diabetes technology (Promotional content from Sanofi)

Diabetes and endocrinology

8 August 2022

MAT-XU-2201218 (v1.0) | October 2022

In this episode, Professor Partha Kar looks into the ongoing inequalities in uptake and awareness of continuous glucose monitoring (CGM). Despite recent advances in access to CGM through the NHS for people with type 1 diabetes, there exist both racial and socioeconomic disparities in use of this technology.¹

In addition, Professor Kar considers aspects of CGM access for people with type 1 and type 2 diabetes and examines the causes of, and potential solutions to, inequalities in the use of CGM.

Reference

Catherine JP, et al. EClinicalMedicine. 2021;42:101186.

UK Prescribing information for Toujeo^® (insulin glargine 300 U/mL) can be accessed by clicking here.

Republic of Ireland Prescribing information for Toujeo^® (insulin glargine 300 U/mL) can be accessed by clicking here.

Adverse events should be reported.

Great Britain and Northern Ireland reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to [email protected].

Republic of Ireland reporting forms and information can be found at www.hpra.ie; email: [email protected]. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to [email protected].